免疫实践咨询委员会关于在≥18岁成人中使用Moderna COVID-19疫苗的建议及mRNA COVID-19疫苗基础系列剂量延长间隔的考虑——美国,2022年2月
mRNA-1273(Moderna)COVID-19疫苗于2020年12月获FDA紧急使用授权,ACIP发布≥18岁人群的临时推荐。2022年1月31日FDA批准该疫苗的生物制品许可申请,2022年2月4日ACIP基于证据到推荐框架将临时推荐修改为≥18岁人群的标准推荐,并考虑基础系列 doses 延长至8周间隔。
要点
- ACIP于2022年2月4日将Moderna COVID-19疫苗在≥18岁人群中的临时推荐修改为标准推荐。
- Moderna COVID-19疫苗基础系列为2剂肌肉注射,每剂100 μg(0.5 mL),间隔4周。
- CDC指南指出8周间隔可能对部分青少年和成人是最优的。
核心结论
- ACIP于2022年2月4日将Moderna COVID-19疫苗在≥18岁人群中的临时推荐修改为标准推荐。
- 自临时推荐发布以来收集的额外信息增加了确定性,即预防有症状和无症状SARS-CoV-2感染、住院和死亡的利益超过Moderna COVID-19疫苗相关风险。
研究设计与样本
- ACIP COVID-19疫苗工作组基于证据到推荐框架,该框架采用GRADE方法对证据质量进行分级。
- ACIP考虑了初始临床试验数据、临床试验额外随访时间、真实世界疫苗有效性研究和授权后疫苗安全性监测。
- ACIP还考虑了真实世界中首剂间隔8周接种时mRNA疫苗有效性和安全性的比较,而非临床试验中使用的原始间隔(BNT162b2为3周,Moderna COVID-19疫苗为4周)。
主要发现
- Moderna COVID-19疫苗基础系列为2剂肌肉注射,每剂100 μg(0.5 mL),间隔4周。
- CDC已提供指南,指出8周间隔可能对部分青少年和成人是最优的。
关键数值与推荐
- ACIP将Moderna COVID-19疫苗在≥18岁人群中的临时推荐修改为标准推荐。
- FDA于2022年1月31日批准Moderna COVID-19疫苗(Spikevax,ModernaTX, Inc.)在≥18岁人群中的生物制品许可申请。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA), and the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use among persons aged ≥18 years (1), which was adopted by CDC. During December 19, 2020-January 30, 2022, approximately 204 million doses of Moderna COVID-19 vaccine were administered in the United States (2) as a primary series of 2 intramuscular doses (100 μg [0.5 mL] each) 4 weeks apart. On January 31, 2022, FDA approved a Biologics License Application (BLA) for use of the Moderna COVID-19 vaccine (Spikevax, ModernaTX, Inc.) in persons aged ≥18 years (3). On February 4, 2022, the ACIP COVID-19 Vaccines Work Group conclusions regarding recommendations for the use of the Moderna COVID-19 vaccine were presented to ACIP at a public meeting. The Work Group's deliberations were based on the Evidence to Recommendation (EtR) Framework,* which incorporates the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach† to rank evidence quality. In addition to initial clinical trial data, ACIP considered new information gathered in the 12 months since issuance of the interim recommendations, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring. ACIP also considered comparisons of mRNA vaccine effectiveness and safety in real-world settings when first doses were administered 8 weeks apart instead of the original intervals used in clinical trials (3 weeks for BNT162b2 [Pfizer-BioNTech] COVID-19 vaccine and 4 weeks for Moderna COVID-19 vaccine). Based on this evidence, CDC has provided guidance that an 8-week interval might be optimal for some adolescents and adults. The additional information gathered since the issuance of the interim recommendations increased certainty that the benefits of preventing symptomatic and asymptomatic SARS-CoV-2 infection, hospitalization, and death outweigh vaccine-associated risks of the Moderna COVID-19 vaccine. On February 4, 2022, ACIP modified its interim recommendation to a standard recommendation§ for use of the fully licensed Moderna COVID-19 vaccine in persons aged ≥18 years.
引用
- Wallace M, Moulia D, Blain AE, et al. The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35298454. doi:10.15585/mmwr.mm7111a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。